Outcomes in 46 patients with sustained engraftment who survived >21 days
| Endpoint . | Total Patients/ Patients at Risk (%) . |
|---|---|
| GVHD | |
| Acute | |
| Grade II-IV | 33/42 (78) |
| Grade III-IV | 7/42 (17) |
| Chronic | 20/32 (62) |
| Relapse | |
| Patients with RA | 1/13 (8) |
| Patients with RAEB | 3/19 (19) |
| Patients with RAEB-T/AML | 6/16 (37) |
| Patients with CMML | 0/2 (0) |
| Patients surviving | 22 (44) |
| Total deaths | 28 (56) |
| Before Day 100 after transplantation | 15 (30) |
| After Day 100 after transplantation | 13 (26) |
| Endpoint . | Total Patients/ Patients at Risk (%) . |
|---|---|
| GVHD | |
| Acute | |
| Grade II-IV | 33/42 (78) |
| Grade III-IV | 7/42 (17) |
| Chronic | 20/32 (62) |
| Relapse | |
| Patients with RA | 1/13 (8) |
| Patients with RAEB | 3/19 (19) |
| Patients with RAEB-T/AML | 6/16 (37) |
| Patients with CMML | 0/2 (0) |
| Patients surviving | 22 (44) |
| Total deaths | 28 (56) |
| Before Day 100 after transplantation | 15 (30) |
| After Day 100 after transplantation | 13 (26) |